TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00927069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab every other week
Description: Adalimumab 40mg injection every other week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab every other week
Description: Adalimumab 40mg injection every other week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Every Week
Description: Adalimumab 40mg injection every week for the last 12 weeks of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Every Week
Description: Adalimumab 40mg injection every week for the last 12 weeks of study.
Study: NCT02922777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB324
Description: 75 mg/m2 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 given IV every 21 days
Study: NCT01937143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity intervention
Description: Pamphlet with information about pain management during infant immunizations at birth of a newborn infant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity intervention
Description: Pamphlet and video with information about pain management during immunizations at birth of a newborn infant

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General information about infant immunizations at birth of a newborn infant
Study: NCT00002880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: 50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
Study: NCT03973658

Intervention type: DEVICE
Intervention: Hearing aids
Description: Fitting of hearing aids (for the first time)
Study: NCT01549353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gum chewing
Study: NCT03866200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: 125 mg/day or 5 ml once per day for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml once per day for 90 days
Study: NCT01381848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
Study: NCT00567320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline up to 2 mg a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill or Placebo
Description: Placebo
Study: NCT02450682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Study: NCT02952456

Intervention type: OTHER
Intervention: interview with a psychologist
Description: interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy

Intervention type: OTHER
Intervention: interview with a psychologist
Description: interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
Study: NCT03866200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 ml once per day for 90 days
Study: NCT01916395

Intervention type: DRUG
Intervention: sumatriptan and Treximet
Description: sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
Study: NCT01129752

Intervention type: OTHER
Intervention: No intervention
Description: there is no intervention for this study
Study: NCT01346800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
Study: NCT01453504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHAP
Description: Dexamethasone, Cytarabine, Cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DHAP
Description: Dexamethasone, Cytarabine, Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study: NCT00995371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MILD® (Minimally Invasive Lumbar Decompression)
Description: Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
Study: NCT01904487

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]flumazenil
Description: \[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiagabine
Description: Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
Study: NCT02134886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01665638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Study: NCT03275922

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo ZNS
Description: Placebo Zolmitriptan Nasal Spray

Intervention type: DRUG
Group type: OTHER
Intervention: ZNS
Description: Zolmitriptan Nasal Spray
Study: NCT02342093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20EE+DRSP
Description: Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
Study: NCT04133064

Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor
Description: The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
Study: NCT02952456

Intervention type: OTHER
Intervention: interview with a psychologist
Description: interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
Study: NCT05428020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling foley catheter
Description: short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No foley catheter
Description: No foley catheter is placed for surgery
Study: NCT04366791

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy
Description: Undergo low-dose radiation therapy
Study: NCT03275922

Intervention type: DRUG
Group type: OTHER
Intervention: ZNS
Description: Zolmitriptan Nasal Spray
Study: NCT02482844

Intervention type: OTHER
Group type: OTHER
Intervention: pacemaker implantation

Intervention type: OTHER
Group type: OTHER
Intervention: holter implantation
Study: NCT02650583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Enhancing Connections Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03569462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile WeChat intervention
Description: Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
Study: NCT05088577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg
Description: Daily consumption of two whole eggs during 8 weeks
Study: NCT03569462

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
Study: NCT01980888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
Study: NCT05088577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Annatto-enriched egg
Description: Daily consumption of two whole eggs enriched with annatto during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg whites - Control
Description: Daily consumption of two eggs whites during 8 weeks
Study: NCT04156919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fooya!™
Description: fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fooya!™
Description: fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WordSearch
Description: We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
Study: NCT02443220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electric acupoint stimulation)
Description: transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEAS
Description: transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia
Study: NCT02071303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg will be given to 70 women before the procedure.
Study: NCT03056599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple drug microinjection
Description: This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIVO device
Description: Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
Study: NCT03167567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence of a medical clown during labor
Description: Presence of a medical clown during labor
Study: NCT02821143

Intervention type: OTHER
Group type: OTHER
Intervention: usual palliative care
Description: Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above.
Study: NCT01258998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03274999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear™ Application
Description: Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear™ Application
Description: Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
Study: NCT03726567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Roux-en-Y surgery
Study: NCT03859830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line
Description: The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AK200 Ultra S, extracorporeal circulation conduct of blood purification
Description: The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
Study: NCT00002931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=7, daily X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 20 mg/kg by 2 hours infusion daily X 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 3 gm/m2 IV over 30 minutes X 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 425 mg/m2 as 24 hour continuous infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Given in two divided infusions on day -2 and day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Two cycles of high dose chemotherapy followed by stem cell reinfusion
Study: NCT03861988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg over 40 minutes, intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg over 40 minutes, intravenous.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (placebo)
Description: Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
Study: NCT01106469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 25mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 250mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 1500mg once daily (with 250mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 100mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 1000mg once daily (with 250mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 500mg once daily (with 250mg tablets)
Study: NCT03224598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution 40%
Description: A-101 Topical Solution 40%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution 40%
Description: A-101 Topical Solution 40%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution 40%
Description: A-101 Topical Solution 40%
Study: NCT05252260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diode Laser
Description: Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
Study: NCT01665638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-peptide
Description: Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-peptide
Description: Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
Study: NCT01980888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match idelalisib administered orally twice daily